Human RCTPubMed ID: 38562789·2024

Cardiovascular Outcomes with Retatrutide: Effects on Endothelial Function and Vascular Inflammation

Marso SP, Bornstein SR, Gupta N, et al.

Journal of the American College of Cardiology, 2024 · n = 298

Key finding

Retatrutide improved brachial artery FMD by 2.8 ± 1.2% vs 0.3 ± 1.4% placebo; PWV decreased by 0.9 ± 0.4 m/s; high-sensitivity CRP reduced 38% vs 8% placebo.

Summary

Mechanistic substudy examining vascular endothelial function (FMD), arterial stiffness (PWV), and inflammatory biomarkers (CRP, IL-6, TNF-α) with retatrutide.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT